dacomitinib dacomitinib dacomitinib, sold under the brand name vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (nsclc). it is a selective and irreversible inhibitor of egfr. dacomitinibclinical datapronunciationdak" oh mi' ti nib trade namesvizimproother namespf-00299804ahfs/drugs.commonographmedlineplusa618055license data us dailymed: dacomitinib routes ofadministrationby mouthatc codel01eb07 (who) legal statuslegal status ca: ℞-only us: ℞-only eu: rx-only in general: ℞ (prescription only) pharmacokinetic databioavailability80%protein binding98%metabolismcyp2d6, cyp3a4metaboliteso-desmethyl-dacomitinibelimination half-life70 hrsexcretion79% faeces, 3% urineidentifiers iupac name (2e)-n--4-(1-piperidinyl)-2-butenamide cas number1110813-31-4 ypubchem cid11511120iuphar/bps7422drugbankdb11963chemspider9685914unii2xjx250c20keggd09883as salt: d10514chebichebi:132268chemblchembl2105719pdb ligand1c9 (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid50149493 chemical and physical dataformulac24h25clfn5o2molar mass469.95 g·mol−13d model (jsmol)interactive image smiles coc1=c(c=c2c(=c1)n=cn=c2nc3=cc(=c(c=c3)f)cl)nc(=o)/c=c/cn4ccccc4 inchi inchi=1s/c24h25clfn5o2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15h,2-4,9-11h2,1h3,(h,30,32)(h,27,28,29)/b6-5+key:lvxjqmnhjwshet-aatrikpksa-n dacomitinib has advanced to several phase iii clinical trials. the january 2014 results of the first trials were disappointing, with a failure to meet the study goals. additional phase iii trials are ongoing. in 2017, results of a trial comparing dacomitinib to gefitinib for nsclc (driven by mutated egfr) were announced. dacomitinib was approved for medical use in the united states in september 2018, in japan in 2019, and in the european union in 2019, for the treatment of non-small cell lung cancer with epidermal growth factor receptor (egfr) gene mutation.